Hosted on MSN2mon
Vera started at buy by Goldman Sachs, atacicept potential citedGoldman Sachs has initiated coverage of Vera Therapeutics (NASDAQ:VERA) with a buy rating, citing the potential of its drug candidate atacicept and a recent pullback in the stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback